“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” “This is the first report of spindle cell sarcoma BRAF ...
The selective BRAF inhibitors vemurafenib (Zelboraf, Roche/Plexxikon) and dabrafenib (Tafinlar, GlaxoSmithKline) have significantly improved survival in patients with BRAF V600–mutant metastatic ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
BRAF and MEK inhibitors are effective in treating resectable melanoma with BRAF V600 mutations, achieving significant pathological responses. The combination therapy significantly improves ...
LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...
“Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression” “Inhibitors ...
In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...
BERKELEY, Calif. & JERUSALEM--(BUSINESS WIRE)--Novellus, a precision-oncology drug development company, announced today that it has entered into an exclusive worldwide license agreement with Plexxikon ...
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...
PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results